Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.49 |
| ▸ | ALK | Q9UM73 | 2/20 | 0.48 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.46 |
| ▸ | NTRK3 | Q16288 | 1/20 | 0.46 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | DDX3X | O00571 | 2/20 | 0.45 |
| ▸ | RAB9A | P51151 | 4/20 | 0.44 |
| ▸ | NPC1 | O15118 | 3/20 | 0.44 |
| ▸ | TP53 | P04637 | 3/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | SNCA | P37840 | 2/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.44 |
| ▸ | GPR142 | Q7Z601 | 1/20 | 0.44 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12767126 | 0.96 | ALK (0.51) | EPHX2ALKNTRK1NTRK3NTRK2 | |
| SCHEMBL1499610 | 0.93 | DDX3X (0.49) | ALKKMT2ADDX3XRAB9ANPC1 | |
| SCHEMBL12766951 | 0.92 | GPR142 (0.51) | EPHX2ALKNTRK1NTRK3NTRK2 | |
| SCHEMBL12767119 | 0.91 | P2RX7 (0.50) | DDX3X | |
| SCHEMBL12766918 | 0.88 | GPR142 (0.53) | ALKNTRK1NTRK3NTRK2RAB9A | |
| SCHEMBL12767302 | 0.87 | ALK (0.49) | EPHX2ALKNTRK1NTRK3NTRK2 | |
| SCHEMBL12766961 | 0.86 | SMN1; SMN2 (0.53) | EPHX2KMT2APOLBDDX3XRAB9A | |
| SCHEMBL12767135 | 0.85 | EPHX2 (0.51) | EPHX2ALKKMT2ARAB9ANPC1 | |
| SCHEMBL12766924 | 0.85 | KCNK3 (0.49) | KMT2ADDX3XRAB9ANPC1TP53 | |
| SCHEMBL21336158 | 0.83 | ALK (0.43) | EPHX2ALKNTRK1NTRK3NTRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2235000-B1 | CHEMICAL MOLECULES THAT INHIBIT THE SLICING MECHANISM FOR TREATING DISEASES RESULTING FROM SPLICING ANOMALIES | CENTRE NAT RECH SCIENT (FR) | 2020-06-17 | — | — | EP | disclosed |
| US-10654813-B2 | Chemical molecules that inhibit the slicing mechanism for treating diseases resulting from splicing anomalies | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2020-05-19 | — | — | US | disclosed |
| US-10538485-B2 | Compounds for use as therapeutic agents affecting P53 expression and/or activity | ABIVAX (FR) | 2020-01-21 | — | — | US | disclosed |
| EP-3536691-A1 | CHEMICAL MOLECULES THAT INHIBIT THE SPLICING MECHANISM FOR TREATING DISEASES RESULTING FROM SPLICING ANOMALIES | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE - CNRS (FR) | 2019-09-11 | — | — | EP | disclosed |
| US-20190022037-A1 | CHEMICAL MOLECULES THAT INHIBIT THE SLICING MECHANISM FOR TREATING DISEASES RESULTING FROM SPLICING ANOMALIES | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2019-01-24 | — | — | US | disclosed |
| US-20180127353-A1 | COMPOUNDS FOR USE AS THERAPEUTIC AGENTS AFFECTING P53 EXPRESSION AND/OR ACTIVITY | ABIVAX (FR) | 2018-05-10 | — | — | US | disclosed |
| US-20180127353-A1 | COMPOUNDS FOR USE AS THERAPEUTIC AGENTS AFFECTING P53 EXPRESSION AND/OR ACTIVITY | ABIVAX (FR) | 2018-05-10 | — | — | US | disclosed |
| US-9890112-B2 | Compounds for use as therapeutic agents affecting p53 expression and/or activity | ABIVAX (FR) | 2018-02-13 | — | — | US | disclosed |
| US-9890112-B2 | Compounds for use as therapeutic agents affecting p53 expression and/or activity | ABIVAX (FR) | 2018-02-13 | — | — | US | disclosed |
| US-20160166519-A1 | CHEMICAL MOLECULES THAT INHIBIT THE SLICING MECHANISM FOR TREATING DISEASES RESULTING FROM SPLICING ANOMALIES | CT NATIONALE DE RECH SCIENT (FR) | 2016-06-16 | — | — | US | disclosed |
| US-9233931-B2 | Chemical molecules that inhibit the slicing mechanism for treating diseases resulting from splicing anomalies | CENTRE NATIONALE DE RECHERCHE SCIENTIFIQUE (FR) | 2016-01-12 | — | — | US | disclosed |
| US-9233931-B2 | Chemical molecules that inhibit the slicing mechanism for treating diseases resulting from splicing anomalies | CENTRE NATIONALE DE RECHERCHE SCIENTIFIQUE (FR) | 2016-01-12 | — | — | US | disclosed |
| US-20140206690-A1 | COMPOUNDS FOR USE AS THERAPEUTIC AGENTS AFFECTING P53 EXPRESSION AND/OR ACTIVITY | SOCIETE SPLICOS (FR) | 2014-07-24 | — | — | US | disclosed |
| US-20140206690-A1 | COMPOUNDS FOR USE AS THERAPEUTIC AGENTS AFFECTING P53 EXPRESSION AND/OR ACTIVITY | SOCIETE SPLICOS (FR) | 2014-07-24 | — | — | US | disclosed |
| US-20140155436-A1 | CHEMICAL MOLECULES THAT INHIBIT THE SLICING MECHANISM FOR TREATING DISEASES RESULTING FROM SPLICING ANOMALIES | CENTRE NATIONAL DE RECHERCHE SCIENTIFIQUE (FR) | 2014-06-05 | — | — | US | disclosed |
| US-20140155436-A1 | CHEMICAL MOLECULES THAT INHIBIT THE SLICING MECHANISM FOR TREATING DISEASES RESULTING FROM SPLICING ANOMALIES | CENTRE NATIONAL DE RECHERCHE SCIENTIFIQUE (FR) | 2014-06-05 | — | — | US | disclosed |
| WO-2012131656-A2 | COMPOUNDS FOR USE AS THERAPEUTIC AGENTS AFFECTING P53 EXPRESSION AND/OR ACTIVITY | SOCIÉTÉ SPLICOS (FR) | 2012-10-04 | — | — | WO | disclosed |
| EP-2505198-A1 | Compounds for use as therapeutic agents affecting p53 expression and/or activity | Société Splicos (FR) | 2012-10-03 | — | — | EP | disclosed |
| US-20110053975-A1 | CHEMICAL MOLECULES THAT INHIBIT THE SLICING MECHANISM FOR TREATING DISEASES RESULTING FROM SPLICING ANOMALIES | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS (FR) | 2011-03-03 | — | — | US | disclosed |
| US-20110053975-A1 | CHEMICAL MOLECULES THAT INHIBIT THE SLICING MECHANISM FOR TREATING DISEASES RESULTING FROM SPLICING ANOMALIES | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS (FR) | 2011-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160166519-A1 | CHEMICAL MOLECULES THAT INHIBIT THE SLICING MECHANISM FOR TREATING DISEASES RESULTING FROM SPLICING ANOMALIES | RBM17, RBM22, SF3B1 | EPHX2 4594/4885ALK 4751/4885NTRK1 4868/4885 |
| US-20190022037-A1 | CHEMICAL MOLECULES THAT INHIBIT THE SLICING MECHANISM FOR TREATING DISEASES RESULTING FROM SPLICING ANOMALIES | RBM17, RBM22, PRPF40A | EPHX2 4664/4885ALK 4654/4885NTRK1 4859/4885 |
| US-10654813-B2 | Chemical molecules that inhibit the slicing mechanism for treating diseases resulting from splicing anomalies | RBM17, RBM22, PRPF40A | EPHX2 4664/4885ALK 4654/4885NTRK1 4859/4885 |
| US-20180127353-A1 | COMPOUNDS FOR USE AS THERAPEUTIC AGENTS AFFECTING P53 EXPRESSION AND/OR ACTIVITY | TP53, TP53BP1, BCOR | EPHX2 4705/4885ALK 932/4885NTRK1 1777/4885 |
| US-20140155436-A1 | CHEMICAL MOLECULES THAT INHIBIT THE SLICING MECHANISM FOR TREATING DISEASES RESULTING FROM SPLICING ANOMALIES | RBM17, SF3B5, SF3B1 | EPHX2 2572/4885ALK 4727/4885NTRK1 4879/4885 |
| US-10538485-B2 | Compounds for use as therapeutic agents affecting P53 expression and/or activity | TP53, TP53BP1, BCOR | EPHX2 4705/4885ALK 932/4885NTRK1 1777/4885 |
| US-20140206690-A1 | COMPOUNDS FOR USE AS THERAPEUTIC AGENTS AFFECTING P53 EXPRESSION AND/OR ACTIVITY | TP53, CBR3, TP53BP1 | EPHX2 4581/4885ALK 775/4885NTRK1 1258/4885 |
| US-20110053975-A1 | CHEMICAL MOLECULES THAT INHIBIT THE SLICING MECHANISM FOR TREATING DISEASES RESULTING FROM SPLICING ANOMALIES | RBM17, SF3B5, SF3B1 | EPHX2 2572/4885ALK 4727/4885NTRK1 4879/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.